骨代谢指标检测在乳腺癌骨转移早期诊断中的应用价值

目的探讨骨代谢指标血清骨钙素（GBP）、Ⅰ型胶原羧基末端肽（ICTP）和尿羟脯氨酸（uHOP）早期诊断乳腺癌骨转移的应用价值。方法对86例原发性乳腺癌和20例正常女性分别采用放射免疫法测定血清BGP、ICTP和uHOP，用ECT核素骨扫描确定乳腺癌有无骨转移。结果无骨转移乳腺癌患者与正常人之间血清BGP、ICTP和uHOP水平差异无统计学意义（P〉0．05），随访2年中32例血清BGP、ICTP和UHOP水平升高，其中29例平均在3个月后ECT核素骨扫描示骨转移，骨转移后血清BGP、ICTP和uHOP水平较转移前明显升高（P〈0．01）。结论血清GBP、ICTP和uHOP在乳腺癌骨转移的早期诊断方面有重要应用价值，且能比LECT核素骨扫描较早发现骨转移。

Application value of bone metabolic index testing in the diagnosis of bone metastasis tumor from the breast carcinoma

Objective To investigate the application value of GBP, ICTP and uHOP in early diagnosis of bone metastasis from breast carcinoma （BMBC）. Methods The serum levels of BGP, ICTP and uHOP of 86 patients with primary breast carcinoma and 20 normal women were detected through radioimmunoassay respectively. Emergency Communication Terminal （ECT） radionuclide bone scan was used to confirm whether bone metastasis occured or not. Results The differences of serum levels of BGP, ICTP and uHOP between breast carcinoma patients without bone metastasis and the normal people were not statistically significant （P〉0.05）. In the 2-year follow-up, 32 patients presented elevation of BGP, ICTP and uHOP. The ECT radionuclide bond scan of 29 patients showed bone metastasis 3 months later averagely. The levels of BGP, ICTP and uHOP increased significantly after bone metastasis （P〈0.01）. Conclusions The serum levels of BGP, ICTP and urine uHOP have application value in the early diagnosis of bone metastasis from breast carcinomas. They could help discover bone metastasis before ECT radionuelide bone scanning.